Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glasdegib in Japanese patients with hematologic malignancies
NCT02038777Phase 1Completed
- Sponsor
- Pfizer
- Start
- Mar 2014
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of glasdegib in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (6 cohorts), sponsored by Pfizer. Primary endpoints: Dose-limiting Toxicities, Treatment Emergent Adverse Events and 3 more. Started Mar 2014; status: completed.
02
Drugs
glasdegib
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02038777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02038777.